Browse > Article
http://dx.doi.org/10.4062/biomolther.2015.026

A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1  

De, Umasankar (School of Pharmacy, Sungkyunkwan University)
Kundu, Soma (College of Pharmacy, Pusan National University)
Patra, Nabanita (College of Pharmacy, Pusan National University)
Ahn, Mee Young (Department of Oral & Maxillofacial Pathology, College of Dentistry, Wonkwang Bone Regeneration Institute, Daejeon Dental Hospital, Wonkwang University)
Ahn, Ji Hae (School of Pharmacy, Sungkyunkwan University)
Son, Ji Yeon (School of Pharmacy, Sungkyunkwan University)
Yoon, Jung Hyun (College of Pharmacy, Pusan National University)
Moon, Hyung Ryoung (College of Pharmacy, Pusan National University)
Lee, Byung Mu (School of Pharmacy, Sungkyunkwan University)
Kim, Hyung Sik (School of Pharmacy, Sungkyunkwan University)
Publication Information
Biomolecules & Therapeutics / v.23, no.5, 2015 , pp. 434-441 More about this Journal
Abstract
Histone deacetylase (HDAC) inhibitors are considered novel agents for cancer chemotherapy. We previously investigated MHY219, a new HDAC inhibitor, and its potent anticancer activity in human prostate cancer cells. In the present study, we evaluated MHY219 molecular mechanisms involved in the regulation of prostate cancer cell migration. Similar to suberanilohydroxamic acid (SAHA), MHY219 inhibited HDAC1 enzyme activity in a dose-dependent manner. MHY219 cytotoxicity was higher in LNCaP ($IC_{50}=0.67{\mu}M$) than in DU145 cells ($IC_{50}=1.10{\mu}M$) and PC3 cells ($IC_{50}=5.60{\mu}M$) after 48 h of treatment. MHY219 significantly inhibited the HDAC1 protein levels in LNCaP and DU145 cells at high concentrations. However, inhibitory effects of MHY219 on HDAC proteins levels varied based on the cell type. MHY219 significantly inhibited LNCaP and DU145 cells migration by down-regulation of matrix metalloprotease-1 (MMP-1) and MMP-2 and induction of tissue inhibitor of metalloproteinases-1 (TIMP-1). These results suggest that MHY219 may potentially be used as an anticancer agent to block cancer cell migration through the repression of MMP-1 and MMP-2, which is related to the reduction of HDAC1.
Keywords
HDAC inhibitor; MHY219; MMPs; Migration; Prostate cancer;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Abbas, A. and Gupta. S. (2008) The role of histone deacetylases in prostate cancer. Epigenetics 3, 300-309.   DOI
2 Ahn, M. Y., Kang, D. O., Na, Y. J., Yoon, S., Choi, W. S., Kang, K. W., Chung, H. Y., Jung, J. H., Min, D. S. and Kim, H. S. (2012) Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing. Cancer Lett. 325, 189-199.   DOI   ScienceOn
3 Catalona, W. J. (1994) Management of cancer of the prostate. N. Engl. J. Med. 331, 996-1004.   DOI
4 Chambers, A. F. and Matrisian. L. M. (1997) Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89, 1260-1270.   DOI
5 Chiu, H. W., Yeh, Y. L., Wang, Y. C., Huang, W. J., Chen, Y. A., Chiou, Y. S., Ho, S. Y., Lin, P. and Wang, Y. J. (2013) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. PLoS One 8, e76340.   DOI
6 Duffy, M. J, Maguire, T. M., Hill, A., McDermott, E. and O'Higgins, N. (2000) Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2, 252-257.   DOI
7 Emanuele, S., Lauricella, M. and Tesoriere, G. (2008) Histone deacetylase inhibitors: apoptotic effects and clinical implications. Int. J. Oncol. 33, 637-646.
8 Fulda, S. (2008) Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr. Cancer Drug Targets 8,132-140.   DOI   ScienceOn
9 Glozak, M. A. and Seto, E. (2007) Histone deacetylases and cancer. Oncogene 26, 5420-5432.   DOI
10 Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E. and Robson, C. N. (2004a) Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59, 177-189.   DOI
11 Halkidou, K., Cook, S., Leung, H.Y., Neal, D. E. and Robson, C. N. (2004b) Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur. Urol. 45, 382-389.   DOI
12 Jung, K. W., Won, Y. J, Kong, H. J., Oh, C. M., Seo, H. G. and Lee, J. S. (2013) Prediction of cancer incidence and mortality in Korea, 2013. Cancer Res. Treat. 45, 15-21.   DOI   ScienceOn
13 Kim, H. J., Park, M. K., Kim, S. Y. and Lee, C. H. (2014) Novel suppressive effects of ketotifen on migration and invasion of MDA-MB-231 and HT-1080 cancer cells. Biomol. Ther. 22, 540-546.   DOI
14 Kim, M. S., Son, M. W., Kim, W. B., Park, Y. I. and Moon, A. (2000) Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype. Cancer Lett. 157, 23-30.   DOI
15 Laurenzana, A., Balliu, M., Cellai, C., Romanelli, M. N. and Paoletti, F. (2013) Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells. PLoS One 8, e58267.   DOI
16 LeRoith, D., Baserga, R., Helman, L., Roberts, C.T.Jr. (1995) Insulinlike growth factors and cancer. Ann. Intern. Med. 122, 54-59.   DOI
17 Levy, D. E., Lapierre, F., Liang, W., Ye, W., Lange, C. W., Li, X., Grobelny, D., Casabonne, M., Tyrrell, D., Holme, K., Nadzan, A. and Galardy, R. E. (1998) Matrix metalloproteinase inhibitors: a structure-activity study. J. Med. Chem. 41,199-223.   DOI
18 Min, K. N., Joung, K. E., Kim, D. K. and Sheen, Y. Y. (2012) Anti-cancer effect of IN-2001 in MDA-MB-231 human breast cancer. Biomol. Ther. 20, 313-319.   DOI
19 Liotta, L. A., Steeg, P. S. and Stetler-Stevenson, W. G. (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327-336.   DOI
20 Liotta, L. A. (1986) Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. 46, 1-7.   DOI
21 Pacheco, M. M., Mourao, M., Mantovani, E. B., Nishimoto, I. N. and Brentani, M. M. (1998) Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin. Exp. Metastasis 16, 577-585.   DOI
22 Patra, N., De, U., Kim, T. H., Lee, Y. J., Ahn, M. Y., Kim, N. D., Yoon, J. H., Choi, W. S., Moon, H. R., Lee, B. M. and Kim, H.S. (2013) A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells. Biomed. Pharmacother. 67, 407-415   DOI
23 Prins, G. S. (2008) Endocrine disruptors and prostate cancer risk. Endocr. Relat. Cancer 15, 649-656.   DOI
24 Pulukuri, S. M. and Rao, J. S. (2008) Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int. J. Oncol. 32, 757-765.
25 Robbins. A. R., Jablonski, S. A., Yen, T. J., Yoda, K., Robey, R., Bates, S. E. and Sackett, D. L. (2005) Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle 4, 717-726.   DOI
26 Zhang, L., Liu, N., Xie, S., He, X., Zhou, J., Liu, M., Li, D. (2014) HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process. Cancer Biol. Ther. 15, 1561-1570   DOI
27 Seligson, D. B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M. and Kurdistani, S. K. (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435, 1262-1266.   DOI
28 Seo, J., Min, S. K., Park, H. R., Kim, D. H., Kwon, M. J., Kim, L. S. and Ju, Y. S. (2014) Expression of histone deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in invasive ductal carcinomas of the breast. J. Breast Cancer 17, 323-331.   DOI
29 Weichert, W., Roske, A., Gekeler, V., Beckers, T., Stephan, C., Jung, K., Fritzsche, F. R., Niesporek, S., Denkert, C., Dietel, M. and Kristiansen, G. (2008) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer 98, 604-610.   DOI
30 Zhao, W., Han, H. B. and Zhang, Z. Q. (2011) Suppression of lung cancer cell invasion and metastasis by connexin43 involves the secretion of follistatin-like 1 mediated via histone acetylation. Int. J. Biochem. Cell Biol. 43, 1459-1468.   DOI